342 related articles for article (PubMed ID: 23525511)
1. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
[TBL] [Abstract][Full Text] [Related]
5. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
[TBL] [Abstract][Full Text] [Related]
8. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
Berger WE; Bensch GW; Weinstein SF; Skoner DP; Prenner BM; Shekar T; Nolte H; Teper AA
Pediatr Pulmonol; 2014 May; 49(5):441-50. PubMed ID: 24019197
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
Maspero JF; Nolte H; Chérrez-Ojeda I;
J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
15. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD.
Weinstein C; Staudinger H; Scott I; Amar NJ; LaForce C
Respir Med; 2011 Jul; 105(7):979-88. PubMed ID: 21398104
[TBL] [Abstract][Full Text] [Related]
16. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
17. Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination.
LaForce C; Weinstein C; Nathan RA; Weinstein SF; Staudinger H; Meltzer EO
J Asthma; 2011 Aug; 48(6):625-31. PubMed ID: 21726121
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
Noonan M; Leflein J; Corren J; Staudinger H
BMC Pediatr; 2009 Jul; 9():43. PubMed ID: 19594937
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
[TBL] [Abstract][Full Text] [Related]
20. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
